A Pilot Study to Assess Healing of Erosive Esophagitis in Patients Randomized to Conventional PPI Doses Versus Dosing Based on CYP2C19 Genotype

Summary

This study is being done to determine if the dosing of proton pump inhibitor (PPI) medication based on CYP2C19 genotype-derived phenotype leads to improved healing of erosive esophagitis compared to conventional PPI medication dosing.

Eligibility

Age range

18–90 years

Sex

All

Healthy volunteers

Yes

Interventions

• Drug
  CYP2C19 based dosing Proton Pump Inhibitors

  Pantoprazole dosing based on CYP2C19 phenotypes

• Drug
  Conventional proton pump inhibitor dose

  conventional PPI dose of Pantoprazole 40 mg once or twice daily

Location